For its first fiscal quarter (ending July 31), Champions Oncology Inc (NASDAQ: CSBR) has reported E.P.S. of $0.10 compared to $-0.19 a year ago. E.P.S. were $-0.25 for the latest four quarters through July 31 versus $-0.56 for the same period a year ago.
Recent Price Action
Champions Oncology Inc (NASDAQ: CSBR) stock closed at $4.07 on 9/11/24 after a large increase of 3.0%. Moreover, exceptionally high trading volume at 2030% of normal accompanied the advance. The stock has declined -2.0% during the last week and has been weak relative to the market over the last nine months.
Current PriceTarget Research Rating
Reflecting future returns on capital that are forecasted to be below the cost of capital, CSBR is expected to be a modest Value Eraser.
Champions Oncology is currently unrated.
Rating Review
The stock is currently unrated.
Be the first to comment